How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice?
Objective: To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer. Results: Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with...
| Publicado en: | Abdominal Radiology Vol. 45; no. 12; pp. 4031 - 4040 |
|---|---|
| Autores principales: | , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Dec2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147338344&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 147338344 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2366004X JT14 jtl: Abdominal Radiology issn: 2366004X maglogo: N pubinfo: dt: Dec2020 vid: 45 iid: 12 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 147338344 144113172 10.1007/s00261-020-02496-5 147338344 ppf: 4031 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: How should radiologists incorporate non-imaging prostate cancer biomarkers into daily practice? aug: au: Rajwa, Pawel Syed, Jamil Leapman, Michael S. affil: Department of Urology, Medical University of Silesia, 41-800, Zabrze, Poland sug: ab: Objective: To review the current body of evidence surrounding non-imaging biomarkers in patients with known or suspected prostate cancer. Results: Several non-imaging biomarkers have been developed and are available that aim to improve risk estimates at several clinical junctures. For patients with suspicion of prostate cancer who are considering first-time or repeat biopsy, blood- and urine-based assays can improve the prediction of harboring clinically significant disease and may reduce unnecessary biopsy. Blood- and urine-based biomarkers have been evaluated in association with prostate MRI, offering insights that might augment decision-making in the pre and post-MRI setting. Tissue-based genomic and proteomic assays have also been developed that provide independent assessments of prostate cancer aggressiveness that can complement imaging. Conclusion: A growing number of non-imaging biomarkers are available to assist in clinical decision-making for men with known or suspected prostate cancer. An appreciation for the intersection of imaging and biomarkers may improve clinical care and resource utilization for men with prostate cancer. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|